Long-term outcome with dasatinib after imatinib failure in chronic-phase chronic myeloid leukemia: follow-up of a phase 3 study.

@article{Shah2014LongtermOW,
  title={Long-term outcome with dasatinib after imatinib failure in chronic-phase chronic myeloid leukemia: follow-up of a phase 3 study.},
  author={Neil Pravin Shah and François Guilhot and Jorge E. Cortes and Charles A Schiffer and Philipp le Coutre and Tim Henrik Br{\"u}mmendorf and Hagop M Kantarjian and Andreas Hochhaus and Philippe Rousselot and Hesham Mohamed and Diane I Healey and Michael Cunningham and Giuseppe Saglio},
  journal={Blood},
  year={2014},
  volume={123 15},
  pages={2317-24}
}
We present long-term follow-up of a dasatinib phase 3 study of patients with imatinib-resistant/-intolerant chronic myeloid leukemia (CML). In the CA180-034 study, 670 patients with imatinib-resistant/-intolerant CML in chronic phase (CML-CP) received dasatinib 100 mg once daily, 50 mg twice daily, 140 mg once daily, or 70 mg twice daily. At 6 years, 188 (28%) of 670 patients remained on study treatment. Estimated 6-year protocol-defined progression-free survival (PFS) rates were 49%, 51%, 40… CONTINUE READING